A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
- Summary
- Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids. Advanced means the cancer has spread nearby or to other parts in the body and cannot be removed with surgery. In this trial, researchers want to learn if the trial medicine called MK-2010, given alone or with other treatments, can treat advanced solid tumors. MK-2010 is designed to help the immune system fight cancer. The goals of this trial are to learn: * About the safety of MK-2010 as monotherapy and in combinations and if participants tolerate them. Tolerate means participants will receive trial treatment unless they need to stop it due to health problems. * How many participants who receive MK-2010 as monotherapy and in combination respond to treatment. Respond means the cancer gets smaller or goes away.
- Short title
- A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
- Official title
- A Phase 2, Open-label Clinical Study to Evaluate the Safety and Efficacy of MK-2010 as Monotherapy and in Combination
- Control arm
- Active comparator
- Registry reports results
- Listing at source
- Listed
- Recruitment status
- Not yet recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Completion date
- 2030-07-28
- First posted
- 2026-08-31
- Registry last updated
- 2026-10-08
- Primary completion date
- 2028-09-26
- Start date
- 2026-10-27
- Participants
- Participant count basis
- Estimated
- Planned participants
- Protocol amendments
- Number of sites
- Data monitoring committee
- Registry sponsor category
- Industry
- Lead sponsor
- Merck Sharp & Dohme LLC
- Source registry
- ClinicalTrials.gov
- Registry ID
- NCT07793942
- ClinicalTrials.gov ID
- NCT07793942
- Registry record
- Open registry record
- Allocation
- Not randomised
- Model
- Parallel groups
- Purpose
- Treatment
- Masking
- No masking
Number of Participants with Adverse Events (AEs)
Timeframe: Up to approximately 24 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Discontinue Study Treatment Due to an AE
Timeframe: Up to approximately 24 months
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention.
Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Timeframe: Up to approximately 28 days
DLT is defined as any drug-related adverse event (AE) observed during the DLT evaluation period that results in a change to a given dose or a delay in initiating the next dose.
Objective Response Rate (ORR)
Timeframe: Up to approximately 24 months
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.
Duration of Response (DOR)
Timeframe: Up to approximately 48 months
For participants who demonstrate confirmed CR or PR per RECIST 1.1 as assessed by BICR, duration of response is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.
Area Under the Curve From Time 0 to Last (AUC0-last) of MK-2010
Timeframe: Predose and at designated time points up to approximately 24 months
Blood samples will be collected to determine the AUC0-last of MK-2010.
Area Under the Curve From Time 0 to the End of the Dosing Interval (AUC0-tau) of MK-2010
Timeframe: Predose and at designated time points up to approximately 24 months
Blood samples will be collected to determine the AUC0-tau of MK-2010.
Trough Concentration (Ctrough) of MK-2010
Timeframe: Predose and at designated time points up to approximately 24 months
Blood samples will be collected to determine Ctrough of MK-2010.
Maximum Concentration (Cmax) of MK-2010
Timeframe: Predose and at designated time points up to approximately 24 months
Blood samples will be collected to determine Cmax of MK-2010.
Incidence of Antidrug Antibodies (ADAs) to MK-2010
Timeframe: Predose and at designated time points up to approximately 24 months
Blood samples will be collected to determine ADAs of MK-2010.
- Sex
- All
- Age groups
- Adults, Older adults
- Minimum age
- 18 Years
- Healthy volunteers
- No
- Has radiographically measurable disease per protocol
- If to receive oral study treatment, has the ability to swallow and retain oral medication and does not have gastrointestinal abnormalities that may alter absorption
- Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if diagnosed with HIV
- Has adequate organ function per protocol
- Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease if diagnosed with HIV
- Has a history of posterior reversible encephalopathy syndrome (PRES) or seizure disorder
- Has hepatic encephalopathy, hepatorenal syndrome, or Child-Pugh class B or more severe liver cirrhosis
- Has a history of confirmed inflammatory bowel disease
- Has a serious active nonhealing wound, ulcer, and/or bone fracture
- Has a history of myocarditis or cardiomyopathy
- Has a history of or current severe cardiovascular and cerebrovascular diseases
- Is currently receiving any anticoagulants
- Has a diagnosis of immunodeficiency
- Has a known additional malignancy that is progressing or required active treatment within the past 3 years
- Has known active central nervous system metastases and/or carcinomatous meningitis
- Has active autoimmune disease that required systemic treatment in the past 2 years (hormonal supplementation [eg, thyroxine, insulin, or physiologic corticosteroid] is allowed)
- Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD
- Has a history of stem cell/solid organ transplant
- Has not adequately recovered from major surgery or from central venous access device placement, or has ongoing surgical complications
- New Jersey Cancer Care ( Site 7002)Belleville, United States
- START Astera, LLC ( Site 0220)East Brunswick, United States
- Taylor Cancer Research Center ( Site 9500)Maumee, United States
- Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8001)Eugene, United States
- Cantonal Hospital St.Gallen ( Site 1100)Sankt Gallen, Switzerland
- CHUV (centre hospitalier universitaire vaudois) ( Site 1101)Lausanne, Switzerland
- MK-2010-002
- 2025
- U1111-1325-1503
- 2025-523102-32-00
Related records
Drugs (13)
- Belzutifan
- Carboplatin
- Cisplatin
- Epinephrine
- Fluorouracil
- Gemcitabine
- Leucovorin
- Levoleucovorin
- Nab-paclitaxel
- Oxaliplatin
- Paclitaxel
- Pembrolizumab
- Pemetrexed